Dormir bien no solo significa alcanzar las famosas ocho horas recomendadas, sino también lograr que ese descanso sea continuo y sin interrupciones. La investigación científica ha demostrado que dormir de un tirón aporta beneficios físicos, cognitivos y emocionales …
Dormir de un tirón: la ciencia detrás de un sueño continuo y reparador Read More »
While Bruton’s tyrosine kinase inhibitors are often hailed as the next big breakthrough in multiple sclerosis, Immunic Therapeutics and others are leveraging neuroprotective targets and remyelination to keep the disease at bay.
Beyond BTK Inhibitors: Next Gen MS Treatments Could Transcend Symptom Management Read More »
Smarter design through targeted delivery and human-relevant testing can save the industry from costly safety failures.
Gene Therapy’s Future Hinges on the Economics of Safety Read More »
As industry leaders gather at the annual event in Phoenix, the cell and gene therapy space remains in a state of flux, with M&A activity and regulatory support signaling momentum while commercialization challenges continue to hinder broader investor interest.
Meeting on the Mesa Arrives Amid Mixed Signals for Cell and Gene Therapy Read More »
Barad, chief digital and technology officer at HSS, outlined his approach to evaluating AI tools and how the orthopedic hospital uses the technology.
Hospital for Special Surgery’s Ashis Barad says AI must solve real problems Read More »
The company plans to launch the device in Europe late next week, providing competition for AtriCure’s AtriClip product.
Medtronic wins CE mark for Penditure LAA exclusion device Read More »
Expanded exemptions for orphan drugs could mean prolonged protections for top-selling drugs like Merck’s Keytruda, which was initially approved under this designation in 2014.
CMS Finalizes Stronger Protections for Orphan Drugs Against IRA Price Negotiations Read More »
Jeanne Marrazzo, former director of the National Institutes of Allergy and Infectious Disease, was formally terminated Thursday after months on administrative leave, after filing a whistleblower report.
Fired NIAID Director Claims Ouster was Payback for Whistleblower Report Read More »
Following up on previous, dimly received issuances, a new set of ideas published by the FDA to streamline regulatory pathways for cell and gene therapies ‘for small populations’ is receiving a warmer welcome—but experts warn it will take more to turn the tide for the fraught therapeutic space.
Findings from the Phase III VESALIUS-CV study reinforce the cholesterol-lowering benefit of Repatha in high-risk patients without prior cardiovascular disease, for which the drug was approved in August 2024.
Amgen Builds Case for Repatha to Prevent Heart Disease With Late-Stage Data Read More »
